Glenmark receives FDA OK for generic Pataday OTC
Glenmark has received the Food and Drug Administration’s clearance for olopatadine hydrochloride ophthalmic solution, 0.2% OTC, which is the generic of Alcon’s Pataday Once Daily Relief Ophthalmic Solution.
Olopatadine Hydrochloride Ophthalmic Solution 0.2% OTC, will be distributed in the United States by Glenmark Therapeutics, USA.
[Read more: Glenmark releases generic Travatan Z]
The Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC) market achieved annual sales of approximately $50.7 million, per Nielsen syndicated data for the latest 52 weeks' period ending Feb. 22, 2025.
Marc Kikuchi, president and business head of North America at Glenmark said, "We are pleased to continue to expand our OTC ophthalmic portfolio. The addition of olopatadine hydrochloride ophthalmic solution USP, 0.2% highlights our commitment to meeting market needs and providing quality over-the-counter solutions for our customers."
[Read more: Glenmark debuts Olopatadine Hydrochloride Ophthalmic Solution OTC]